INOVIO PHARMACEUTICALS, INC. — Department of Defense SBIR Phase I: Inovio Pharmaceuticals current minimally invasive dermal electroporation prototype device,

Description

Inovio Pharmaceuticals current minimally invasive dermal electroporation prototype device, which uses low voltage parameters to achieve both high and consistent levels of immunogenicity, offers an attractive option as an efficient and tolerable method for delivering DNA vaccinations in a clinical setting. For this submission, we propose to develop a multi-headed electroporation platform based on optimized version of the current device. This new device would remain an effective means to deliver DNA vaccines while maintaining the tolerability of a surface dermal electroporation method. Additionally, this device could simultaneously delivery two or more DNA vaccines at spatially separate sites, negating any issues with interference and reducing vaccine burden. The production of such a device which could simultaneously deliver multiple plasmid vaccines would offer a significant advance in the field of DNA vaccinations.